Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pill may help when blood pressure meds aren't enough

NCT ID NCT06344104

Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new drug called baxdrostat in 326 adults whose high blood pressure was not controlled even with two or more medications. Participants took either 1 mg, 2 mg of baxdrostat, or a placebo daily for 12 weeks. The main goal was to see if baxdrostat could lower systolic blood pressure more than placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

326 people

The number who actually took part.

Started

Apr 2024

Finished

Apr 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Male or female participants must be ≥ 18 years old. * Mean seated SBP on automated office blood pressure measurement (AOBPM) ≥ 140 mmHg at Screening. * Fulfil at least 1 of the following 2 criteria: 1. uHTN subpopulation: have a stable regimen (≥ 4 weeks) of 2 antihypertensive medications, from different therapeutic classes (at least one must be a diuretic), at maximum tolerated dose in the judgement of the Investigator. 2. rHTN subpopulation: have a stable regimen (≥ 4 weeks) of ≥ 3 antihypertensive medications, from different therapeutic classes (at least one must be a diuretic), at maximum tolerated dose in the judgement of the Investigator. * Estimated glomerular filtration rate ≥ 45 mL/min/1.73m2 at Screening. * Serum potassium (K+) level ≥ 3.5 and \< 5.0 mmol/L at Screening.• Mean seated SBP on AOBPM ≥ 135 mmHg at Baseline. Exclusion Criteria: * Mean seated SBP on AOBPM ≥ 170 mmHg. * Mean seated DBP on AOBPM ≥ 105 mmHg. * Serum sodium level (Na+) \< 135 mmol/L at Screening. * Has the following known secondary causes of hypertension: renal artery stenosis, uncontrolled or untreated hyperthyroidism, uncontrolled or untreated hypothyroidism, pheochromocytoma, Cushing's syndrome, aortic coarctation. * NYHA functional heart failure class IV at Screening.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Resistant hypertension are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hypertensive disorder resistant hypertension

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Resistant hypertension Uncontrolled hypertension

Contacts and locations

Locations

  • Research Site

    Bahía Blanca, 8000, Argentina

  • Research Site

    CABA, C1426, Argentina

  • Research Site

    Ciudad de Buenos Aires, C1419AHL, Argentina

  • Research Site

    San Miguel de Tucumán, T4000ICL, Argentina

  • Research Site

    San Nicolás de los Arroyos, B2900DPA, Argentina

  • Research Site

    Coffs Harbour, 02450, Australia

  • Research Site

    Gosford, 2250, Australia

  • Research Site

    Hoppers Crossing, 3029, Australia

  • Research Site

    Ipswich, 4305, Australia

  • Research Site

    Baotou, 014010, China

  • Research Site

    Beijing, 100029, China

  • Research Site

    Beijing, 100044, China

  • Research Site

    Bengbu, 233004, China

  • Research Site

    Changde, 415000, China

  • Research Site

    Changsha, 410015, China

  • Research Site

    Changsha, 430033, China

  • Research Site

    Changzhou, 272100, China

  • Research Site

    Chengdu, 610041, China

  • Research Site

    Chongqing, 400010, China

  • Research Site

    Chongqing, 400014, China

  • Research Site

    Chongqing, 400042, China

  • Research Site

    Deyang, 618000, China

  • Research Site

    Guangzhou, 510100, China

  • Research Site

    Hangzhou, 310014, China

  • Research Site

    Ha’erbin, 150001, China

  • Research Site

    Hefei, 230601, China

  • Research Site

    Heze, 274099, China

  • Research Site

    Jiujiang, 332000, China

  • Research Site

    Luoyang, 471000, China

  • Research Site

    Meihekou, 135022, China

  • Research Site

    Nanchang, 330009, China

  • Research Site

    Nanchong, 637900, China

  • Research Site

    Nanjing, 210009, China

  • Research Site

    Panjin, 124009, China

  • Research Site

    Sanya, 572000, China

  • Research Site

    Shanghai, 200025, China

  • Research Site

    Shanghai, 200040, China

  • Research Site

    Shenyang, 110004, China

  • Research Site

    Shenyang, 110016, China

  • Research Site

    Taiyuan, 030024, China

  • Research Site

    Tianjin, 300457, China

  • Research Site

    Tianjin, China

  • Research Site

    Wuhan, 430010, China

  • Research Site

    Wuhan, 430022, China

  • Research Site

    Wuhan, 430060, China

  • Research Site

    Xianyang, 712000, China

  • Research Site

    Xianyang, 750004, China

  • Research Site

    Xuzhou, 221000, China

  • Research Site

    Yangzhou, 225001, China

  • Research Site

    Yinchuan, 750001, China

  • Research Site

    Zigong, 643021, China

  • Research Site

    Hong Kong, 00000, Hong Kong

  • Research Site

    Hong Kong, Hong Kong

  • Research Site

    Bangalore, 560 092, India

  • Research Site

    Belagavi, 590016, India

  • Research Site

    Chūōku, 103-0027, Japan

  • Research Site

    Chūōku, 260-0804, Japan

  • Research Site

    Hamamatsu, 430-0929, Japan

  • Research Site

    Kagoshima, 890-8520, Japan

  • Research Site

    Koga-shi, 306-0232, Japan

  • Research Site

    Meguro-ku, 153-0051, Japan

  • Research Site

    Minatoku, 108-0073, Japan

  • Research Site

    Minokamo Shi, 505-8510, Japan

  • Research Site

    Osaka, 530-8480, Japan

  • Research Site

    Toshima-ku, 171-0014, Japan

  • Research Site

    Tsukuba, 305-0861, Japan

  • Research Site

    Yokohama, 236-0004, Japan

  • Research Site

    Iloilo City, 5000, Philippines

  • Research Site

    Quezon City, 1112, Philippines

  • Research Site

    Ivanovo, 153012, Russia

  • Research Site

    Moscow, 111539, Russia

  • Research Site

    Moscow, 119991, Russia

  • Research Site

    Moscow, 121552, Russia

  • Research Site

    Moscow, 129327, Russia

  • Research Site

    Saint Petersburg, 195067, Russia

  • Research Site

    Saint Petersburg, 197341, Russia

  • Research Site

    Seoul, 03080, South Korea

  • Research Site

    Seoul, 03722, South Korea

  • Research Site

    Seoul, 04763, South Korea

  • Research Site

    Seoul, 05505, South Korea

  • Research Site

    Ankara, 06800, Turkey (Türkiye)

  • Research Site

    Ankara, 5000, Turkey (Türkiye)

  • Research Site

    Cordaleo, 35575, Turkey (Türkiye)

  • Research Site

    Edirne, 22030, Turkey (Türkiye)

  • Research Site

    Kahramanmaraş, 46100, Turkey (Türkiye)

  • Research Site

    Kayseri, 38039, Turkey (Türkiye)

  • Research Site

    Kocaeli, 41380, Turkey (Türkiye)

  • Research Site

    Mersin, 33343, Turkey (Türkiye)

  • Research Site

    Can Tho, 900000, Vietnam

  • Research Site

    Hanoi, 100000, Vietnam

  • Research Site

    Ho Chi Minh City, 700000, Vietnam

  • Research Site

    Hochiminh City, 700000, Vietnam

  • Research Site

    Hochiminh, 70000, Vietnam

More trials for these conditions

Other studies related to the condition(s) this trial covers.